-
1
-
-
33646263592
-
Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain
-
10.1158/0008-5472.CAN-05-1265, 16618770
-
Kawakami K, Terabe M, Kawakami M, Berzofsky JA, Puri RK. Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain. Cancer Res 2006, 66:4434-4442. 10.1158/0008-5472.CAN-05-1265, 16618770.
-
(2006)
Cancer Res
, vol.66
, pp. 4434-4442
-
-
Kawakami, K.1
Terabe, M.2
Kawakami, M.3
Berzofsky, J.A.4
Puri, R.K.5
-
2
-
-
0036813331
-
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
-
10.1034/j.1600-065X.2002.18803.x, 12445278
-
Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002, 188:22-32. 10.1034/j.1600-065X.2002.18803.x, 12445278.
-
(2002)
Immunol Rev
, vol.188
, pp. 22-32
-
-
Scanlan, M.J.1
Gure, A.O.2
Jungbluth, A.A.3
Old, L.J.4
Chen, Y.T.5
-
3
-
-
0035871986
-
Interleukin-13 receptor as a unique target for anti-glioblastoma therapy
-
10.1002/1097-0215(200102)9999:9999<::AID-IJC1182>3.0.CO;2-N, 11291041
-
Husain SR, Joshi BH, Puri RK. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 2001, 92:168-175. 10.1002/1097-0215(200102)9999:9999<::AID-IJC1182>3.0.CO;2-N, 11291041.
-
(2001)
Int J Cancer
, vol.92
, pp. 168-175
-
-
Husain, S.R.1
Joshi, B.H.2
Puri, R.K.3
-
4
-
-
0029934957
-
Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR)
-
Puri RK, Leland P, Obiri NI, Husain SR, Kreitman RJ, Haas GP, Pastan I, Debinski W. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 1996, 87:4333-4339.
-
(1996)
Blood
, vol.87
, pp. 4333-4339
-
-
Puri, R.K.1
Leland, P.2
Obiri, N.I.3
Husain, S.R.4
Kreitman, R.J.5
Haas, G.P.6
Pastan, I.7
Debinski, W.8
-
5
-
-
0036705806
-
Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model
-
2040009, 12435859
-
Kawakami K, Husain SR, Kawakami M, Puri RK. Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model. Mol Med 2002, 8:487-494. 2040009, 12435859.
-
(2002)
Mol Med
, vol.8
, pp. 487-494
-
-
Kawakami, K.1
Husain, S.R.2
Kawakami, M.3
Puri, R.K.4
-
6
-
-
0031029303
-
Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein
-
Husain SR, Obiri NI, Gill P, Zheng T, Pastan I, Debinski W, Puri RK. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin Cancer Res 1997, 3:151-156.
-
(1997)
Clin Cancer Res
, vol.3
, pp. 151-156
-
-
Husain, S.R.1
Obiri, N.I.2
Gill, P.3
Zheng, T.4
Pastan, I.5
Debinski, W.6
Puri, R.K.7
-
7
-
-
33749005099
-
Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy
-
10.1002/cncr.22134, 16902988
-
Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy. Cancer 2006, 107:1407-1418. 10.1002/cncr.22134, 16902988.
-
(2006)
Cancer
, vol.107
, pp. 1407-1418
-
-
Kioi, M.1
Kawakami, M.2
Shimamura, T.3
Husain, S.R.4
Puri, R.K.5
-
8
-
-
0028859363
-
Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin
-
Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res 1995, 1:1253-1258.
-
(1995)
Clin Cancer Res
, vol.1
, pp. 1253-1258
-
-
Debinski, W.1
Obiri, N.I.2
Powers, S.K.3
Pastan, I.4
Puri, R.K.5
-
9
-
-
0029041783
-
A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4
-
10.1074/jbc.270.28.16775, 7622490
-
Debinski W, Obiri NI, Pastan I, Puri RK. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem 1995, 270:16775-16780. 10.1074/jbc.270.28.16775, 7622490.
-
(1995)
J Biol Chem
, vol.270
, pp. 16775-16780
-
-
Debinski, W.1
Obiri, N.I.2
Pastan, I.3
Puri, R.K.4
-
10
-
-
0036284481
-
Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin
-
Joshi BH, Kawakami K, Leland P, Puri RK. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin Cancer Res 2002, 8:1948-1956.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 1948-1956
-
-
Joshi, B.H.1
Kawakami, K.2
Leland, P.3
Puri, R.K.4
-
11
-
-
11844306593
-
Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli
-
10.1016/j.pep.2004.10.012, 15642470
-
Joshi BH, Puri RK. Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli. Protein Expr Purif 2005, 39:189-198. 10.1016/j.pep.2004.10.012, 15642470.
-
(2005)
Protein Expr Purif
, vol.39
, pp. 189-198
-
-
Joshi, B.H.1
Puri, R.K.2
-
12
-
-
16544381261
-
Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model
-
10.3171/jns.2004.101.6.1004, 15597761
-
Kawakami K, Kawakami M, Kioi M, Husain SR, Puri RK. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. J Neurosurg 2004, 101:1004-1011. 10.3171/jns.2004.101.6.1004, 15597761.
-
(2004)
J Neurosurg
, vol.101
, pp. 1004-1011
-
-
Kawakami, K.1
Kawakami, M.2
Kioi, M.3
Husain, S.R.4
Puri, R.K.5
-
13
-
-
33947723884
-
Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases
-
Joshi BH, Hogaboam C, Dover P, Husain SR, Puri RK. Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases. Vitam Horm 2006, 74:479-504.
-
(2006)
Vitam Horm
, vol.74
, pp. 479-504
-
-
Joshi, B.H.1
Hogaboam, C.2
Dover, P.3
Husain, S.R.4
Puri, R.K.5
-
14
-
-
33947547455
-
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group
-
10.1200/JCO.2006.08.1117, 17327604
-
Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007, 25:837-844. 10.1200/JCO.2006.08.1117, 17327604.
-
(2007)
J Clin Oncol
, vol.25
, pp. 837-844
-
-
Kunwar, S.1
Prados, M.D.2
Chang, S.M.3
Berger, M.S.4
Lang, F.F.5
Piepmeier, J.M.6
Sampson, J.H.7
Ram, Z.8
Gutin, P.H.9
Gibbons, R.D.10
-
15
-
-
74549138477
-
Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy
-
Shimamura T, Fujisawa T, Husain SR, Joshi B, Puri RK. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy. Clin Cancer Res 2009, 16:577-586.
-
(2009)
Clin Cancer Res
, vol.16
, pp. 577-586
-
-
Shimamura, T.1
Fujisawa, T.2
Husain, S.R.3
Joshi, B.4
Puri, R.K.5
-
16
-
-
79956020311
-
Targeting IL-13Ralpha2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine
-
Fujisawa T, Nakashima H, Nakajima A, Joshi BH, Puri RK. Targeting IL-13Ralpha2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine. Int J Cancer 2010,
-
(2010)
Int J Cancer
-
-
Fujisawa, T.1
Nakashima, H.2
Nakajima, A.3
Joshi, B.H.4
Puri, R.K.5
-
17
-
-
50549096499
-
Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity
-
10.1038/mt.2008.152, 2748750, 18665158
-
Allen C, Paraskevakou G, Iankov I, Giannini C, Schroeder M, Sarkaria J, Puri RK, Russell SJ, Galanis E. Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Mol Ther 2008, 16:1556-1564. 10.1038/mt.2008.152, 2748750, 18665158.
-
(2008)
Mol Ther
, vol.16
, pp. 1556-1564
-
-
Allen, C.1
Paraskevakou, G.2
Iankov, I.3
Giannini, C.4
Schroeder, M.5
Sarkaria, J.6
Puri, R.K.7
Russell, S.J.8
Galanis, E.9
-
18
-
-
10844296758
-
Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells
-
10.1158/0008-5472.CAN-04-0454, 15604287
-
Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 2004, 64:9160-9166. 10.1158/0008-5472.CAN-04-0454, 15604287.
-
(2004)
Cancer Res
, vol.64
, pp. 9160-9166
-
-
Kahlon, K.S.1
Brown, C.2
Cooper, L.J.3
Raubitschek, A.4
Forman, S.J.5
Jensen, M.C.6
-
19
-
-
2642531973
-
Epigenetics in human disease and prospects for epigenetic therapy
-
10.1038/nature02625, 15164071
-
Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429:457-463. 10.1038/nature02625, 15164071.
-
(2004)
Nature
, vol.429
, pp. 457-463
-
-
Egger, G.1
Liang, G.2
Aparicio, A.3
Jones, P.A.4
-
20
-
-
70449725209
-
Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies
-
10.1016/S1474-4422(09)70262-5, 19833297
-
Urdinguio RG, Sanchez-Mut JV, Esteller M. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol 2009, 8:1056-1072. 10.1016/S1474-4422(09)70262-5, 19833297.
-
(2009)
Lancet Neurol
, vol.8
, pp. 1056-1072
-
-
Urdinguio, R.G.1
Sanchez-Mut, J.V.2
Esteller, M.3
-
21
-
-
68349135058
-
Histone modification patterns and epigenetic codes
-
Lennartsson A, Ekwall K. Histone modification patterns and epigenetic codes. Biochim Biophys Acta 2009, 1790:863-868.
-
(2009)
Biochim Biophys Acta
, vol.1790
, pp. 863-868
-
-
Lennartsson, A.1
Ekwall, K.2
-
22
-
-
34249337761
-
Perceptions of epigenetics
-
10.1038/nature05913, 17522671
-
Bird A. Perceptions of epigenetics. Nature 2007, 447:396-398. 10.1038/nature05913, 17522671.
-
(2007)
Nature
, vol.447
, pp. 396-398
-
-
Bird, A.1
-
23
-
-
0036211013
-
Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics
-
10.1093/embo-reports/kvf053, 1084017, 11882541
-
Eberharter A, Becker PB. Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep 2002, 3:224-229. 10.1093/embo-reports/kvf053, 1084017, 11882541.
-
(2002)
EMBO Rep
, vol.3
, pp. 224-229
-
-
Eberharter, A.1
Becker, P.B.2
-
24
-
-
20444479514
-
Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid
-
Kelly WK, Marks PA. Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005, 2:150-157.
-
(2005)
Nat Clin Pract Oncol
, vol.2
, pp. 150-157
-
-
Kelly, W.K.1
Marks, P.A.2
-
25
-
-
20544471104
-
Histone deacetylase inhibitors in programmed cell death and cancer therapy
-
10.4161/cc.4.4.1564, 15738652
-
Marks PA, Jiang X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 2005, 4:549-551. 10.4161/cc.4.4.1564, 15738652.
-
(2005)
Cell Cycle
, vol.4
, pp. 549-551
-
-
Marks, P.A.1
Jiang, X.2
-
26
-
-
33845996135
-
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
-
10.1182/blood-2006-06-025999, 1785068, 16960145
-
Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109:31-39. 10.1182/blood-2006-06-025999, 1785068, 16960145.
-
(2007)
Blood
, vol.109
, pp. 31-39
-
-
Duvic, M.1
Talpur, R.2
Ni, X.3
Zhang, C.4
Hazarika, P.5
Kelly, C.6
Chiao, J.H.7
Reilly, J.F.8
Ricker, J.L.9
Richon, V.M.10
Frankel, S.R.11
-
27
-
-
0034467913
-
Preclinical studies with IL-13PE38QQR for therapy of malignant glioma
-
10.1358/dnp.2000.13.10.858450, 12879131
-
Joshi BH, Husain SR, Puri RK. Preclinical studies with IL-13PE38QQR for therapy of malignant glioma. Drug News Perspect 2000, 13:599-605. 10.1358/dnp.2000.13.10.858450, 12879131.
-
(2000)
Drug News Perspect
, vol.13
, pp. 599-605
-
-
Joshi, B.H.1
Husain, S.R.2
Puri, R.K.3
-
28
-
-
72249115096
-
A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis
-
10.1158/0008-5472.CAN-09-2100, 19887609
-
Fujisawa T, Joshi B, Nakajima A, Puri RK. A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res 2009, 69:8678-8685. 10.1158/0008-5472.CAN-09-2100, 19887609.
-
(2009)
Cancer Res
, vol.69
, pp. 8678-8685
-
-
Fujisawa, T.1
Joshi, B.2
Nakajima, A.3
Puri, R.K.4
-
29
-
-
56449096183
-
Human adrenomedullin up-regulates interleukin-13 receptor alpha2 chain in prostate cancer in vitro and in vivo: a novel approach to sensitize prostate cancer to anticancer therapy
-
10.1158/0008-5472.CAN-08-2810, 19010904
-
Joshi BH, Leland P, Calvo A, Green JE, Puri RK. Human adrenomedullin up-regulates interleukin-13 receptor alpha2 chain in prostate cancer in vitro and in vivo: a novel approach to sensitize prostate cancer to anticancer therapy. Cancer Res 2008, 68:9311-9317. 10.1158/0008-5472.CAN-08-2810, 19010904.
-
(2008)
Cancer Res
, vol.68
, pp. 9311-9317
-
-
Joshi, B.H.1
Leland, P.2
Calvo, A.3
Green, J.E.4
Puri, R.K.5
-
30
-
-
0034162718
-
Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas
-
Joshi BH, Plautz GE, Puri RK. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 2000, 60:1168-1172.
-
(2000)
Cancer Res
, vol.60
, pp. 1168-1172
-
-
Joshi, B.H.1
Plautz, G.E.2
Puri, R.K.3
-
31
-
-
0038262659
-
Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor alpha2 chain in vivo
-
10.1038/sj.gt.3301956, 12808442
-
Kawakami K, Kawakami M, Husain SR, Puri RK. Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor alpha2 chain in vivo. Gene Ther 2003, 10:1116-1128. 10.1038/sj.gt.3301956, 12808442.
-
(2003)
Gene Ther
, vol.10
, pp. 1116-1128
-
-
Kawakami, K.1
Kawakami, M.2
Husain, S.R.3
Puri, R.K.4
-
32
-
-
0038421814
-
Molecular cloning and identification of the human interleukin 13 alpha 2 receptor (IL-13Ra2) promoter
-
10.1215/S1152851702000510, 1920687, 12816724
-
Wu AH, Low WC. Molecular cloning and identification of the human interleukin 13 alpha 2 receptor (IL-13Ra2) promoter. Neuro Oncol 2003, 5:179-187. 10.1215/S1152851702000510, 1920687, 12816724.
-
(2003)
Neuro Oncol
, vol.5
, pp. 179-187
-
-
Wu, A.H.1
Low, W.C.2
-
33
-
-
0035189761
-
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia
-
209432, 11696577
-
He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP, Rifkind RA, Marks PA, Richon VM, Pandolfi PP. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001, 108:1321-1330. 209432, 11696577.
-
(2001)
J Clin Invest
, vol.108
, pp. 1321-1330
-
-
He, L.Z.1
Tolentino, T.2
Grayson, P.3
Zhong, S.4
Warrell, R.P.5
Rifkind, R.A.6
Marks, P.A.7
Richon, V.M.8
Pandolfi, P.P.9
-
34
-
-
72249084921
-
Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824
-
10.1158/0008-5472.CAN-09-1456, 2779578, 19861533
-
Vo DD, Prins RM, Begley JL, Donahue TR, Morris LF, Bruhn KW, de la Rocha P, Yang MY, Mok S, Garban HJ, et al. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res 2009, 69:8693-8699. 10.1158/0008-5472.CAN-09-1456, 2779578, 19861533.
-
(2009)
Cancer Res
, vol.69
, pp. 8693-8699
-
-
Vo, D.D.1
Prins, R.M.2
Begley, J.L.3
Donahue, T.R.4
Morris, L.F.5
Bruhn, K.W.6
de la Rocha, P.7
Yang, M.Y.8
Mok, S.9
Garban, H.J.10
|